DELRAY BEACH, Fla., Aug 6, 2025 /PRNewswire/ -- The global Biopharmaceutical CDMO Market, valued at US$20.51 billion in 2024 stood at US$22.40 billion in 2025 and is projected to advance at a resilient CAGR of 8.8% from 2025 to 2030, culminating in a forecasted valuation of US$34.15 billion by the end of the period. This represents a strong CAGR of 8.8% from 2025 to 2030. The growth is primarily driven by the rising demand for outsourcing services and an increasing need for biologics and biosimilars. However, challenges related to intellectual property rights are anticipated to pose barriers to market growth.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=163964739
Browse in-depth TOC on "Biopharmaceutical CDMO Market"
422 - Tables
57 - Figures
380 - Pages
By Service, the global biopharmaceutical contract manufacturing market is divided into four main service categories: manufacturing, formulation & fill-finish, packaging & labeling, and other services. The formulation & fill-finish segment accounts for the second-largest share of the market due to the rising demand for precision in biologics production, which is crucial for the safety, stability, and efficacy of therapeutic products. As the complexity of biologics increases, the demand for specialized services like formulation development, aseptic filling, and packaging is growing. Contract manufacturing organizations (CMOs) are investing in advanced facilities and technologies to meet this demand, while stringent regulatory requirements and the rise of personalized treatments further enhance the need for these services. This segment is expected to continue its growth and play a key role in delivering innovative treatments to patients.
By Scale of Operation, the commercial operations segment is rapidly growing within the global biopharmaceutical contract manufacturing market, driven by the rising demand for large-scale manufacturing services. The increasing complexity of biologics and advanced therapies necessitates sophisticated facilities and expertise for a smooth transition from clinical trials to commercial production. As approvals for biologics multiply, biopharmaceutical companies turn to CMOs for specialized equipment, state-of-the-art facilities, and trained staff, ensuring compliance with regulatory standards and consistent product quality. Outsourcing allows pharmaceutical firms to concentrate on research, development, and marketing while accessing efficient and flexible manufacturing. Furthermore, advancements in manufacturing technologies and the rise of personalized medicine are fueling this growth, making commercial contract manufacturing essential for the successful global commercialization of complex biopharmaceutical products.
By geography, the biopharmaceutical contract manufacturing market is divided into six regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America leads the market due to its strong pharmaceutical and biotech industries. Recent growth is driven by rising demand for biologics, outsourcing trends, and the region's advanced manufacturing capabilities. North America's robust regulatory environment and support for research and development have created an ideal setting for contract manufacturing, making it a preferred choice for global biopharmaceutical firms. The presence of skilled professionals and enhanced infrastructure further solidifies its position as a key hub in the industry.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=163964739
The key players in the biopharmaceutical contract manufacturing market include Lonza (Switzerland), Thermo Fisher Scientific Inc. (US), WuXi Biologics (China), Catalent, Inc. (US), Samsung Biologics (South Korea), Boehringer Ingelheim International GmbH (Germany), FUJIFILM Holdings Corporation (Japan), AbbVie, Inc. (US), Eurofins Scientific (Luxembourg), GenScript Biotech Corporation (US), AGC Inc. (Japan), Merck KGaA (Germany), JSR Corporation (Japan), IDT Biologika (Germany), Ajinomoto Bio-Pharma (Japan), Agilent Technologies, Inc. (US), and Asahi Kasei Corporation (Japan).
Lonza (Switzerland):
Lonza (Switzerland) has solidified its position as a leading player in the biopharmaceutical contract manufacturing market. The company offers a comprehensive range of services, including the manufacturing of biologic drug substances and products and cGMP manufacturing for cell & gene therapies. Lonza's strong market presence is supported by a wide service portfolio, advanced production facilities, a broad global reach, and continuous investments to expand its manufacturing capabilities. In February 2023, Lonza upgraded its bioconjugation facility in Visp, Switzerland, increasing its capacity to support the development and production of preclinical, clinical, and commercial bioconjugates and antibody-drug conjugates. This enhancement further reinforces Lonza's market leadership and service offerings.
WuXi Biologics (China)
WuXi Biologics (China) is a leading player in the biopharmaceutical contract manufacturing market, providing a comprehensive range of services and maintaining a strong presence in developing countries. Its extensive expertise and service offerings have allowed the company to capture a significant market share and establish itself as a trusted partner in biopharmaceutical manufacturing. Additionally, the company focuses on inorganic growth strategies, such as acquisitions and collaborations, to enhance its capabilities and expand its global footprint. For example, in June 2025, WuXi Biologics announced the construction of a new microbial drug product (DP) manufacturing facility in the Wenjiang district of Chengdu, which will have a drug substance (DS) manufacturing capacity of 60,000 liters.
For more information, Inquire Now!
Related Reports:
Fill Finish Manufacturing Market
Vaccines Market
Monoclonal Antibody Therapeutics Market
Pharmaceutical Contract Manufacturing Market
Drug Discovery Services Market
Get access to the latest updates on Biopharmaceutical CDMO Companies and Biopharmaceutical CDMO Market Size
About MarketsandMarkets:
MarketsandMarkets has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets.com or follow us on Twitter, LinkedIn and Facebook.
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/biopharmaceutical-cdmo-market-worth-us34-15-billion-in-2030-with-8-8-cagr--marketsandmarkets-302523030.html
